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Background: Knowledge about Cystic Fibrosis (CF) in Egypt is very limited. The objective of this study was to screen for CF in Egyptian
children with suggestive clinical features and to identify causative genetic mutations.
Methods: Sixty-one patients from the Chest Unit, Cairo University Children's Hospital, Egypt, were included. Subjects presented with
persistent or recurrent respiratory symptoms, failure to thrive, diarrhea and/or steatorrhea and unexplained persistent jaundice. Patients were
screened using the CF Indicator™ sweat test system (PolyChrome Medical, Inc., Brooklyn Center, MN). A quantitative sweat testing was
conducted on 10 of the 12 positive patients. Seven probands and one sibling underwent molecular analysis by direct DNA sequencing of the
coding region and of the intronic sequences adjacent to the 27 exons of the CFTR gene.
Results: Of 61 patients, 12 (20%) had positive sweat chloride screening. Ten of the 12 patients underwent quantitative sweat testing and were
positive. Eight CFTR sequence changes were identified in seven affected probands and two were confirmed in one sibling by direct DNA
sequencing.
Conclusion: The study results suggest that CF is more common in Egypt than previously anticipated. Larger studies are warranted to identify
the incidence, molecular basis and clinical pattern of CF in the Egyptian population.
© 2006 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.Keywords: Cystic fibrosis screening; CFTR; Non-Caucasian CF; CF indicatorTM sweat test system; CF in Egyptian children1. Introduction
Cystic fibrosis (CF) is a chronic, progressive, recessively
transmitted genetic disorder [1]. It is considered the most
common life-limiting genetic disease in the Caucasian
population [2]. In the United States (U.S.), CF incidence inAbbreviations: CF, Cystic fibrosis; CFTR, Cystic Fibrosis Transmem-
brane Conductance Regulator.
⁎ Corresponding author. Tel.: +1 734 936 4123; fax: +1 734 936 7635.
E-mail address: snasr@umich.edu (S.Z. Nasr).
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doi:10.1016/j.jcf.2006.04.004Caucasian populations is ranging from 1 in 1900 to 1 in 3700
[3]. It is lower among African Americans (1 in 15,000) [3,4]
and Asians (1 in 32,000) [5,6]. However, the incidence in
populations of other ethnic backgrounds, including Egyp-
tians, has not been established [3].
The median age of diagnosis in the U.S. is 6 months and
the mean is 3.3 years. Survival of CF patients has shown
steady improvement, as documented in the U.S. Patient
Registry [4]. As a result of specialized care provided through
accredited centers, the predicted median survival of CF
patients currently is 35.1 years [4]. Improvement in theuropean Cystic Fibrosis Society.
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availability of new medications for CF (e.g. tobramycin
solution for inhalation and recombinant human DNase) [7].
Delayed diagnosis could lead to irreversibly progressive
pulmonary disease and a shortened life span [8].
Minimal information is available concerning the pre-
valence of CF in Egypt, where the disease was presumed to
be extremely rare. A few studies of CF patients from the
Middle East have described the clinical presentation and
limited genetic analyses of the disease [9–19]. Many
children with CF in these populations probably remain
undiagnosed due to lack of clinical suspicion and proper
diagnostic facilities. The objective of this study was to
determine the presence of CF among 61 Egyptian patients
with respiratory and gastrointestinal manifestations similar
to those reported in CF patients [2]. The children were seen
at Cairo University Children's Hospital. A description of
their clinical findings and their molecular genetic analysis
will be presented. This research study was a collaboration
among Cairo University, University of Michigan Health
System, Cystic Fibrosis Center, Ann Arbor, MI and Stanford
University Medical Center, Stanford, CA.
2. Materials and methods
2.1. Subjects
Sixty patients aged 2 months to 2 1/2 years were screened
from Cairo University Children's Hospital—a tertiary care
referral hospital of 300 beds located in Egypt. Subjects were
recruited during a 13 month period (November 2000–
December 2001). High risk patients were selected from the
pulmonology and the gastroenterology outpatient clinics and
inpatient words. Subjects presented with one or more of the
following symptoms were asked to participate in the study:
chronic or recurrent respiratory symptoms, chronic cough,
recurrent pneumonia and/or persistent radiographic abnorm-
alities, gastrointestinal symptoms such as diarrhea, steator-
rhea, rectal prolapse, meconium ileus or hepatobiliary
disease, and/or failure to thrive with no other diagnosis to
explain their clinical condition. A seven-year-old boy was
screened because he presented with symptoms similar to his
sibling, who tested positive for CF in the screening stage.
These two siblings were the only related subjects in the
study.
2.2. Study methods
2.2.1. Qualitative sweat testing
Sixty-one patients were screened for CF using the Model
9800 CF Indicator™ Sweat Test System (Polychrome
Medical (PCM) Inc., Brooklyn Center, Minnesota). This is
a simple, rapid, laboratory-independent sweat test [20–23].
The portable test unit uses pilocarpine iontophoresis for
sweat stimulation followed by placement of a chloride
concentration test patch to collect and analyze the sweat. Theassay provides a qualitative assessment of the sweat chloride
concentration. Results are interpreted based on color change
of the test patch and categorized as follows: CF not present
(negative test), CF possible (test is inconclusive) or CF
present (positive test denoting sweat chloride >60 mEq/L).
The CF Indicator™ sweat test was compared to the Gibson–
Cooke quantitative sweat test [24]. The specificity were
98.9% and 100% and sensitivity were 100% and 100% for
the CF Indicator and Gibson–Cooke sweat test, respectively
[22]. Twelve patients of the 61 tested were positive by this
screen. Patients with repeated inconclusive test results were
considered negative for CF (Group B). Close follow-up of
this group of patients is ongoing with further laboratory re-
evaluation as necessary.
2.2.2. Quantitative sweat testing
Ten of the 12 CF-positive patients were available for
quantitative assessment of sweat chloride for confirmation of
the diagnosis. Sweat gland secretion was stimulated using
the pilocarpine iontophoresis method followed by sample
collection [24]. The chloride level in collected samples was
subsequently measured. At least 50 mg of sweat was
collected for reliable results. Sweat chloride analysis was
repeated twice for all tested patients to confirm the results.
An average of the two readings is shown in Table 2.
2.2.3. PCR amplification
Eight of the twelve positive patients were genetically
tested. Genomic DNA was isolated from blood leukocytes
according to standard procedures for the molecular genetic
analysis of the CFTR gene. Amplification of genomic DNA
was performed using Amplitaq Gold DNA polymerase, 5 U/
μL (Perkin Elmer) and the four 2'-deoxynucleotide 5'-
triphosphates (Amersham Pharmacia). Primer pairs from
intronic sequences that flank individual CFTR exons were
used for amplification of the CFTR gene as described [25].
For exon 1, however, an alternative forward primer was
substituted [26]. The presence and size of amplified products
were confirmed by agarose-gel electrophoresis.
2.2.4. CFTR sequencing analysis
PCR purification was performed by QIAquick PCR
purification or by QIAquick gel extraction (Qiagen). Purified
samples were sequenced directly with fluorescent di-deoxy
terminators (ABI) on an ABI 310 or 377 sequencing
instrument (Applied Biosystems). Sequence interpretation
was facilitated by GCG Sequence Analysis Web alignment
programs (www.Accelrys.com). All identified sequence
changes were confirmed by direct DNA sequencing in the
reverse direction.
3. Results
The study population consisted of 61 patients. We
initially screened 60 patients ranging in age from 2 months
to 2 1/2 years with a mean age of (±SD) 1.1±0.68 years.
Table 1
Summary of demographics and clinical presentation of study population
Demographics Group A Group B All
Number of patients (percent) 12 (20) 49 (80) 61 (100)
Gender M/F 8/4 33/16 41/20
Age (y) 1.63±1.83 ⁎ (0.5–7.0) ⁎⁎ 1.1±0.67 (0.2–2.0) 1.23±0.70 (0.2–7.0)
Clinical presentation
Chronic respiratory symptoms 11 (92) 38 (78) 49 (80)
Abnormal stools/diarrhea 7 (58) 15 (31) 22 (36)
Hepatobiliary disease 1 (8) 15 (31) 16 (27)
Dehydration/excess sweating 5 (42) 6 (12) 11 (18)
Failure to thrive/malnutrition 12 (100) 46 (94) 58 (95)
Digital clubbing 3 (25) 7 (14) 10 (17)
Abnormal clinical chest exam 11 (92) 40 (82) 51 (84)
Suggestive family history 4 (33) 3 (6) 7 (11)
⁎ Mean±SD.
⁎⁎ Range.
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0.63). Patients were divided into two groups based on the
results of sweat chloride testing. Group A consisted of 11
patients (18%) with a positive screening test and Group B
encompassed 49 patients (82%) with negative screening
results. Demographics and clinical presentation of the study
population are illustrated in Table 1. A seven-year-old
patient was included in the screening process after his 2 1/2-
year-old sibling tested positive for CF (Table 2).
A high rate of consanguineous marriage was documented
in the families of the study population, with no significant
difference between the two groups (Group A: 84% and
Group B: 82%). Eleven patients in Group A (92%) and 41
patients in Group B (84%) were breast fed. None of the
patients had nasal polyps or history of meconium ileus.
Table 2 presents clinical characteristics and sequence
analysis of 12 CF patients from 11 unrelated families. In
patients with CF the principal clinical features were growth
failure (weight and length below 5th percentile for age) and
persistent respiratory symptoms. Diarrhea was frequently
described rather than steatorrhea, and one patient developedTable 2
Clinical findings and mutation analysis of the cystic fibrosis patients
Patient number Consanguineous
marriage
Affected
sibling
Age
(y)
Sex Cl
3 Y N 1.5 M Ja
10 Y N 1.1 M PU
13 Y N 0.2 F PU
17 Y N 0.5 M PU
20 Y N 0.7 M PU
22 Y Y 2.5 F PU
23 N N 0.5 F PU
41 Y Y 0.5 F PU
46 Y N 2 M PU
55 N Y 0.7 M PU
58 Y N 0.6 M PU
22/B ⁎ Y Y 7 M PU
1540A>G (M470V): a sequence variant which is a common polymorphism in the
⁎ Sibling of patient 22. Y: Yes, N: No, PULM: pulmonary manifestations, GI:rectal prolapse during follow-up. One patient presented with
jaundice, impaired liver functions and growth failure with no
pulmonary signs or symptoms. However, jaundice and
hepatomegaly were more frequent in Group B than Group
A (26.5% and 14.3% respectively). Ten of the 12 CF positive
patients using qualitative sweat testing were also assessed by
quantitative sweat testing. Sweat chloride concentrations for
the ten patients ranged from 80–120 mmol/l with a mean
(±SD) of 94.3±10.8. One patient (#58) was not available for
either quantitative sweat testing or sequence analysis. He
underwent extensive work up for other causes for his
symptoms, with negative results. Because his symptoms
were consistent with CF and he was positive by the
qualitative sweat testing, he was considered positive for CF.
3.1. Mutation analysis
Eight of the 12 CF-positive patients were genetically
tested. Amplification and direct genomic DNA sequencing
of the 27 CFTR exons in the seven probands and one sibling
revealed a total of eight mutations (Table 2). The ΔF508inical findings Sequence analysis Sweat chloride
(mmol/L)
undice, FTT 1540A>G (M470V)/unidentified 100
LM, GI, FTT 2125A>T (T665S)/unidentified 90
LM, GI, FTT N/A 120
LM, FTT N/A 95
LM, FTT N/A 90
LM, FTT ΔF508/ΔF508 96
LM, FTT 1898+3A>C/4041G>C
(N1303K)
97
LM, GI, FTT 1540A>G (M470V)/unidentified 85
LM, FTT Unidentified/unidentified 90
LM, GI, FTT ΔF508/unidentified 80
LM, FTT N/A N/A
LM, GI, FTT ΔF508/ΔF508 N/A
CFTR gene. In these patients, it is of unclear significance.
diarrhea/steatorrhea, FTT: failure to thrive, N/A: not available.
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homozygous patient whose affected sibling had the same
mutation and also in a patient for whom the second mutation
remained unidentified.
One patient was compound heterozygous for 1898+
3A>C and 4041G>C. The 1898+3A>C mutation is likely
to result in a mRNA splicing defect since it occurs at the
donor splice site of intervening sequence 12. It was
originally identified on a Moroccan chromosome (Cystic
Fibrosis Mutation database http://www.genet.sickkids.on.ca/
cftr/). This mutation is rare in Caucasians and does not reach
the 0.1% threshold of general population frequency to
warrant screening in the U.S. [27]. The 4041G>C mutation
results in an amino acid substitution of an asparagine residue
by lysine at position 1303 (N1303K). This mutation is
relatively common in the Caucasian population and is
included in the ACMG/ACOG recommended carrier screen-
ing panels.
One patient was identified as a carrier of the 2125A>T
(T665S) missense mutation in exon 13a. This rare mutation
was originally identified in a Tunisian CF patient (Cystic
Fibrosis Mutation database http://www.genet.sickkids.on.ca/
cftr/)and is located close to an exonic splice enhancer (ESE).
The mutation may potentially cause aberrant splicing of exon
13 by influencing the polypyrimidine tracts of two cryptic
splice sites [28].
Finally, the 1540A>G (M470V) sequence variant was
detected in two patients in whom no clearly pathogenic
mutations were identified. Although this change is described
as a sequence variant based on its relative frequency (Cystic
Fibrosis Mutation databasehttp://www.genet.sickkids.on.ca/
cftr/), it has been associated with clinical significance when
found in combination with the 5T allele in intron eight [28].
Although our two patients were homozygous for the
common 7T allele in intron eight, it is conceivable that the
M470V amino acid substitution results in a minor contribu-
tion to the development of the phenotypic spectrum of CF
[29–31]. The frequency of the M470Vallele in the Egyptian
population is not known. Considering its common occur-
rence in other populations, however, it is not likely to
significantly contribute to the phenotype of these patients.
4. Discussion
A diagnosis of CF is considered when there are
characteristic symptoms, a history of CF in a sibling, or a
positive newborn screening test, in addition to a positive
sweat test or the detection of two mutations in the CFTR [5].
Cystic fibrosis has been believed to occur infrequently in
Egypt, however the present study suggests that the
occurrence of CF in Egyptian patients is higher than
previously thought. In this small group of high-risk patients,
CF diagnosis was made in 20% of subjects. In a previous
study, neonatal screening for CF was conducted for 18,650
Egyptian infants, using the meconium BM-mec-test (Boeh-
ringer Manheim, Gmbh, Germany). Five infants wereidentified as positive for CF and four were borderline.
Subsequent qualitative sweat testing indicated seven of the
nine babies were positive for CF with an incidence rate of
1:2664 [10]. Two hundred twenty-four patients age 3 days to
7 years were also tested using the same qualitative sweat
chloride testing method (the Orion's Model 417 Skin
Chloride System). The sweat test was considered positive
if the sweat chloride level was greater than 60 mM/L. Four of
these patients tested positive (1.79%) [10]. Neither study
evaluated for the presence or absence of CF-related
symptoms. Few reports have been published about CF
patients in the Middle East [11–19]. These reports indicated
frequencies ranging from 1:5800 in Bahrain [15] to 1:2650 in
Jordan [16].
In the majority of cases (71%) in the United States, the
diagnosis of CF is established by the age of 1 year [2,4]. It is
likely that a delayed diagnosis contributes significantly to the
high prevalence of malnutrition in CF patients [32,33] and
could also lead to irreversibly progressive pulmonary disease
and a shortened life span [8]. The patients who were
diagnosed with CF in our study have been monitored closely.
Appropriate pancreatic supplements, in addition to aggres-
sive treatment plans for their respiratory and GI symptoms,
have been started with positive preliminary results.
The lack of definitive data for the prevalence of CF in
Egypt may reflect underdiagnosis of CF where a significant
proportion of infant morbidity and mortality is caused by
respiratory infections, diarrheal disease and malnutrition
[8,9]. Another confounding factor may be early mortality
caused by severe disease or neonatal complications. In
addition, lack of awareness of the public and medical
community in Egypt, concerning the presentation and
diagnosis of the disease may be a contributing factor to
underdiagnosis of the disease.
The clinical presentations of CF are heterogeneous. The
frequency of clinical manifestations is better described in
populations where the disease is well studied [4]. Due to
genetic and environmental differences among ethnic groups,
CF presentation may also vary between populations. In the
present study, all CF patients had failure to thrive at the time
of diagnosis, 92% had chronic or recurrent respiratory
disease and 58% had an abnormal stool pattern described as
watery diarrhea, as opposed to “steatorrhea” which is more
commonly associated with CF [4]. In contrast, reports from
the North American Cystic Fibrosis Registry [4,5] indicate
that 40.3% of CF patients had failure to thrive, 48.8% had
respiratory symptoms and 32.2% had abnormal stools/
steatorrhea at time of diagnosis. The present study, however,
did select high-risk patients with chronic illness and findings
may be influenced by a delay in diagnosis or indicate a more
severe disease presentation. Clinical phenotypes reported in
studies from other populations in the Middle East suggest a
relatively high incidence of hepatobiliary manifestations in
CF. Hepatobiliary involvement was reported in 4% [15] to
10.9% [11,12] of Middle Eastern patients diagnosed with
CF; in the present study one patient presented primarily with
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involvement is much higher than that reported in the North
American CF Registry [4,5]. Although the studies are
diverse and the populations studied were small in number,
the findings may represent a different spectrum of CF
manifestations in the Middle East.
In our patient population there were more males than
females (67% in both groups) (Table 1). This finding could
reflect a true increase of disease incidence in males or may
suggest more severe disease in females with early demise.
We are not aware of gender-specific referral practices that
may have influenced such results.
The study also revealed a high rate of consanguineous
marriage (84% in Group A, 82% in Group B), higher than the
reported rate for the general population in Egypt (37%) [34].
This finding is not surprising, given that the study specifically
included high risk patients with possible genetic disorders
including CF. Twenty-three percent of our CF patients had a
suggestive family history, which included death of siblings
with undiagnosed conditions and similar symptoms.
The ΔF508 mutation is the most common mutation in
Caucasians, where it accounts for approximately 70% of CF
cases. Reports on CFTR genetic analysis in Middle Eastern
populations have reflected genetic mutations that are distinct
from populations of Northern European descent and putative
novel mutations (e.g. del E672 and IVS21-28G>A) have
been identified [11,33]. In our 7 probands, we expected to
identify 14 mutations, given the autosomal recessive
inheritance pattern of CF. However, only 8/14 mutant alleles
were identified (57%). Direct DNA sequencing has a very
high detection rate (∼99%) for sequence changes in the
CFTR coding region and adjacent splice sites, but is unable
to detect large deletions, mutations in the intervening and
other non-coding sequences, or variants in the promoter.
Thus, it is a possibility that mutations which would escape
detection by sequencing are common in the Egyptian
population, or at the least in this group of patients. Further
studies need to be conducted to test this hypothesis.
In conclusion, this study reveals the need for further
investigation of cystic fibrosis in Egyptian children at an
early age. Previously thought to be extremely rare, the true
incidence of the disease in Egypt needs to be established. Its
true frequency may be obscured by more common condi-
tions such as respiratory infections, diarrhea and malnutrition
as well as other genetic or metabolic diseases. The current
study was limited by the small number of patients and by the
lack of implementation of more standardized diagnostic
measures such as quantitative sweat chloride testing [24].
Further analysis of the clinical manifestations of the disease
in Egyptian children and characterization of the mutation
spectrum are therefore warranted. Finally, establishment of a
CF care program to provide diagnosed patients with specific
treatment plans is necessary to improve the quality of life and
to prolong patient survival. As part of this effort, the
molecular basis of CF should be characterized in a larger
group of Egyptian patients in order to identify commonmutations in this population and to provide confirmation of
the clinical diagnosis.
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